ArticleSouth Asian journal of cancer2025
Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure.
Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims and Objective: This article studies the clinical outcome of patients with multiple myeloma who have renal failure at presentation. Methodology: Patients with multiple myeloma presenting with serum creatinine of more than or equal to 2 mg/dL from outpatient department at Sri Ram Cancer Centre, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India, were screened for baseline serum creatinine and estimated glomerular filtration rate (eGFR). Assessment was done at completion of 6 months from diagnosis-patients' clinical condition, renal response (serum creatinine and eGFR), and disease response as per the International Myeloma Working Group criteria. Results: Final response assessment was done at a follow-up of 6 months. Half of the patients achieved a renal complete response; the highest being in the lenalidomide group (83.3%). Patients with eGFR < 15 mL/min/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.